Market capitalization | $166.84b |
Enterprise Value | $221.15b |
PER (TTM) P/E ratio | 44.47 |
EV/FCF (TTM) EV/FCF | 31.16 |
EV/Sales (TTM) EV/Sales | 7.53 |
P/S ratio (TTM) P/S ratio | 5.68 |
P/B ratio (TTM) P/B ratio | 33.22 |
Dividend yield | 2.74% |
Last dividend (FY23) | $8.52 |
Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.
29 Analysts have issued a Amgen forecast:
29 Analysts have issued a Amgen forecast:
Mar '24 |
+/-
%
|
||
Turnover | 29,353 29,353 |
13%
13%
|
|
Gross income | 19,422 19,422 |
0%
0%
|
|
EBITDA | 11,860 11,860 |
3%
3%
|
EBIT (operating result) EBIT | 7,290 7,290 |
17%
17%
|
Net profit | 3,763 3,763 |
52%
52%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Head office | United States |
CEO | Robert Bradway |
Employees | 26,700 |
Founded | 1980 |
Website | www.amgen.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.